{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Survey Questionnaire
    @if (isset(session()->get('doctor')['vCentralCode']))
    @else
    @endif @if (isset(session()->get('doctor')['vCentralCode']))
    @else
    @endif
  1. In which patient profiles do you screen for ASCVD *
  2. Which methodologies do you employ for screening of ASCVD? *

  3. What according to you are the most common risk factors in Indian patients for developing ASCVD? *
  4. Do you observe any difference between prevalence of ASCVD in male and female patients? *

  5. How many patients of atherosclerotic cardiovascular disease do you see in a week? *

  6. According to you what are the lifestyle modifications most effective in reducing ASCVD risk? (Select any one) *

  7. At which LDL-C level will you prefer to start a patient on pharmacological therapy? *

  8. What is your preferred initial pharmacological therapy for primary prevention of ASCVD? Please mention the agent and dose with which you initiate therapy in ASCVD patients. *
  9. According to your experience which statin has the minimal incidence of myopathy? *

  10. After how many weeks of initiating lipid lowering therapy will you consider modification/up titration in dose if target LDL C levels are not achieved? *

  11. In patients with diabetes mellitus will you recommend early aggressive lipid lowering therapy to mitigate the risk of ASCVD? *

  12. What percentage of your patients do not achieve LDL-C goals in the first 3 months despite statin therapy? *

  13. Which non-statin agents are preferred in your practice for achieving the target LDL-C levels? Please specify the agents and dose *
  14. How many acute myocardial infarction patients do you see in a week? *

  15. Of the acute MI cases you see what percentage of patients are of recurrent MI? *

  16. What strategy do you recommend to prevent recurrent MI? (Choose all applicable options) *

  17. In which patient profiles would you advise ranolazine? *
  18. What are the common challenges during intensification of statin therapy? *
  19. According to your opinion which drug should be preferred in established ASCVD patients having clopidogrel resistance? *
  20. What duration of dual antiplatelet therapy (agent and dose) is preferred in your practice? How long do you prefer to continue dual antiplatelet therapy following ACS? *
  21. Please specify the major concern you have with long term continuation of dual antiplatelet therapy? *
  22. What is the proportion of triple vessel disease among your ASCVD patients? *
  23. Will you consider maintaining patient on single P2Y12 inhibitor following ACS? *

  24. According to your opinion how effective is DASH diet in reducing the risk of ASCVD? *

  25. According to your opinion are CKD patients more prone to myopathy with statins? *

  26. At what eGFR level do you recommend reduction of statin dose in CKD patients? *

  27. What proportion of your patients with ASCVD develop heart failure? Please specify *
  28. According to you which SGLT2i is most effective in preventing cardiac deaths? *